# hepatocellular carcinoma (HCC) - gemini-3.6-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 5
- Task type: PROGNOSIS
- Tissue / sample source: liver tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Google Gemini / gemini-3.6-flash
- Message SHA-256: be503ca72a7bcd2f0eb88c8049c4935f5ef704fb40bd5170c65ca64b33a1d716
- Response HTTP status: 200
- Prompt tokens: 32109
- Completion tokens: 20363
- Reasoning tokens: 9068
- Total tokens: 52472
- API requests reported: 2
- Elapsed seconds: 47.877
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1376.986
- Question handoff seconds: 1390.502
- Final benchmark system: E2seq; file rank 4/5; original repeat 5; model vendor: Google Gemini

---
### Data-Quality Warning & Statistical Overview

**Data-Quality & Technical Saturation Warning:**  
The uploaded survival statistics demonstrate extreme mathematical degeneracy and numerical saturation characteristic of Cox proportional hazards model failure (e.g., complete separation, severe overfitting, or unconstrained penalized estimates). Specifically:
* **Effect Sizes:** 69 genes display identical, biologically implausible Hazard Ratios of $\text{HR} = 5.1847055 \times 10^{21}$ (e.g., *CGB2*, *SLC1A6*, *IRS4*, *OTX2*, *FOXR2*, *MIR182*, *Y_RNA*), while protective genes exhibit infinitely suppressed hazard ratios of $\text{HR} = 1.9287498 \times 10^{-22}$ (e.g., *CENPVL3*, *LOC105372753*, *RP11-506K19.2*). Other risk genes display artificially inflated estimates ranging from $1.7376762 \times 10^5$ to $7.7370224 \times 10^{19}$.
* **$P$-Values and FDR:** All 100 features report $P = 0$ and $\text{FDR} = 0$.
* **Feature Composition:** The input feature set is overwhelmingly dominated by non-coding RNAs, pseudogenes (e.g., *S100A7P1*, *RPL5P21*, *YWHAZP8*, *SNAI1P1*, *ALDH7A1P3*, *NF1P7*), small nuclear/nucleolar RNAs (*RNU6*, *RNU4*, *RN7SK* family), long non-coding RNAs (*LINC00454*, *LINC01665*, *LINC02135*), and unmapped Ensembl loci (*UNMAPPED_ENSEMBL_ENSG00000283631*).

Because no independent validation dataset was provided, **external statistical validation was not performed**. The following multidimensional analysis separates these unstable input survival statistics from functional database annotations, biological pathways, and published literature to yield an exploratory, evidence-grounded interpretation.

---

### 1. Overall Biological Interpretation

The input transcriptomic signature consists of 100 evaluated features associated with Overall Survival (OS) in hepatocellular carcinoma (HCC) tissue: 97 risk-associated features ($\text{HR} > 1$) and 3 protective-associated features ($\text{HR} < 1$). Despite the numerical saturation of the Cox model, integrating the recognizable protein-coding genes and annotated non-coding transcripts highlights four major biological themes in HCC tumor tissue:

1. **Developmental and Lineage-Specific Transcription:** Aberrant re-activation of embryonic or lineage-restricted transcription factors (e.g., *OTX2*, *FOXI1*, *FOXR2*) that govern cell fate, lineage commitment, and oncogenic transcriptional reprogramming in liver malignancies.
2. **Growth Factor Signaling and Metabolic Transport Dysregulation:** Perturbations in metabolic crosstalk and nutrient handling, anchored by insulin receptor substrate signaling (*IRS4*) and high-affinity amino acid/glutamate transport (*SLC1A6*), alongside metabolic pseudogene readouts (*ALDH7A1P3*, *PLA2G10P1*).
3. **Ectopic Ectodermal/Sensory Receptors:** Expression of non-canonical G-protein coupled receptors, specifically ectopic olfactory receptors (*OR2M7*, *OR5M10*, *OR5T2*) and neuroendocrine peptides (*CRH*), which are frequently dysregulated during malignant dedifferentiation.
4. **Non-Coding RNA and Epigenetic Remodeling:** Widespread alteration of small non-coding RNA pathways (including microRNA *MIR182*, Y_RNA species, and spliceosomal snRNAs like *RNU6* and *RNU4* variants) together with novel lncRNAs (*LINC01665*, *LINC02135*, *XKR4-AS1*) and structural pseudogenes (*SNAI1P1*, *HMGB3P27*).

---

### 2. Core Biological Programs

```
                  +-------------------------------------------------------+
                  |  HCC Transcripts Associated with OS (100 Features)   |
                  +-------------------------------------------------------+
                                              |
        +------------------+------------------+------------------+------------------+
        |                  |                  |                  |                  |
        v                  v                  v                  v                  v
+---------------+  +---------------+  +---------------+  +---------------+  +---------------+
|   Program 1   |  |   Program 2   |  |   Program 3   |  |   Program 4   |  |   Program 5   |
| Transcriptional|  | GPCR / Sensory|  | Metabolic &  |  | Non-Coding RNA|  | Spliceosomal &|
| Re-program.   |  |  Signaling    |  | Amino Acid Tx |  | & Post-Tx Reg.|  | RNP Machinery |
|  (Risk-Assoc.)|  |  (Risk-Assoc.)|  |  (Risk-Assoc.)|  | (Mixed-Assoc.)|  |  (Risk-Assoc.)|
+---------------+  +---------------+  +---------------+  +---------------+  +---------------+
| OTX2, FOXR2,  |  | OR2M7, OR5M10,|  | SLC1A6, IRS4, |  | MIR182, Y_RNA,|  | RNU6-1134P,   |
| FOXI1, CGB2   |  | OR5T2, CRH    |  | ALDH7A1P3     |  | LINC01665     |  | RNU4-72P      |
+---------------+  +---------------+  +---------------+  +---------------+  +---------------+
```

#### Program 1: Oncogenic & Developmental Transcriptional Reprogramming
* **Prognostic Association:** Risk-associated ($\text{HR} > 1$).
* **Major Supporting Genes:** *OTX2* ($\text{HR} = 5.1847055 \times 10^{21}$), *FOXR2* ($\text{HR} = 5.1847055 \times 10^{21}$), *FOXI1* ($\text{HR} = 6.6286512 \times 10^{13}$), *CGB2* ($\text{HR} = 5.1847055 \times 10^{21}$).
* **Standardized Pathway:** Reactome: *Generic Transcription Pathway* (R-HSA-212576) / GO: *DNA-binding transcription factor activity* (GO:0003700).
* **Biological Rationale:** *OTX2*, *FOXR2*, and *FOXI1* encode master transcription factors essential during early embryonic patterning and lineage determination. Ectopic activation of *FOXR2* and *OTX2* promotes cell proliferation, stemness, and invasive properties across solid tumors, while gonadotropin subunit *CGB2* reflects oncofetal re-expression.
* **Evidence Strength & Limitations:** Supported by direct dataset signal (risk association) and established functional ontology. However, normal liver tissue expresses minimal *OTX2* or *FOXR2*; elevated expression in tumor tissue may reflect low-frequency stem-like tumor cell subsets or focal genomic amplifications.

#### Program 2: Ectopic GPCR & Chemosensory Signal Transduction
* **Prognostic Association:** Risk-associated ($\text{HR} > 1$).
* **Major Supporting Genes:** *OR2M7* ($\text{HR} = 5.1847055 \times 10^{21}$), *OR5M10* ($\text{HR} = 5.1847055 \times 10^{21}$), *OR5T2* ($\text{HR} = 5.1847055 \times 10^{21}$), *CRH* ($\text{HR} = 1.5102345 \times 10^6$).
* **Standardized Pathway:** KEGG: *G-protein coupled receptor signaling pathway* (hsa04030) / GO: *Detection of chemical stimulus involved in sensory perception of smell* (GO:0007186).
* **Biological Rationale:** Olfactory receptors (*OR2M7*, *OR5M10*, *OR5T2*) form a distinct G-protein coupled receptor (GPCR) cluster. STRING network records show shared signal transduction machinery through arrestins (*ARRB1*, *ARRB2*) and G-protein subunits (*GNAL*, *GNB1*). Ectopic OR expression in solid tumors has been linked to intracellular calcium signaling, altered cell migration, and neuroendocrine-like transdifferentiation.
* **Evidence Strength & Limitations:** Network co-membership and ontology overlap are high among the OR family. Limitations include high sequence homology causing mapping ambiguity during RNA-seq quantification and low absolute tissue abundance in liver samples.

#### Program 3: Amino Acid Transport & Insulin Receptor Docking Dysregulation
* **Prognostic Association:** Risk-associated ($\text{HR} > 1$).
* **Major Supporting Genes:** *SLC1A6* ($\text{HR} = 5.1847055 \times 10^{21}$), *IRS4* ($\text{HR} = 5.1847055 \times 10^{21}$), *ALDH7A1P3* ($\text{HR} = 5.1847055 \times 10^{21}$), *PLA2G10P1* ($\text{HR} = 5.1847055 \times 10^{21}$).
* **Standardized Pathway:** Reactome: *SLC-mediated transport of amino acids* (R-HSA-9958863) / KEGG: *Type II diabetes mellitus* (hsa04930).
* **Biological Rationale:** *SLC1A6* (EAAT4) is a high-affinity sodium-dependent glutamate and L-aspartate transporter (GO:0140009). *IRS4* acts as an insulin receptor substrate protein that hyperactivates PI3K/AKT/mTOR signaling. Together, they represent nutrient uptake adaptations and constitutive metabolic driving signals in aggressive liver tumors.
* **Evidence Strength & Limitations:** Well-defined biochemical annotations in QuickGO and Reactome. However, *SLC1A6* is primarily brain-expressed in GTEx baseline tissue; elevated tumor read counts require verification against tumor-infiltrating non-parenchymal cells or liver progenitor states.

#### Program 4: MicroRNA & Long Non-Coding Post-Transcriptional Networks
* **Prognostic Association:** Mixed (Predominantly Risk-associated; Protective lncRNA loci present).
* **Major Supporting Genes:** *MIR182* ($\text{HR} = 5.1847055 \times 10^{21}$), *LINC01665* ($\text{HR} = 2.7283280 \times 10^7$), *LINC02135* ($\text{HR} = 4986.0118$), *XKR4-AS1* ($\text{HR} = 5.1847055 \times 10^{21}$), *LOC105372753* ($\text{HR} = 1.9287498 \times 10^{-22}$).
* **Standardized Pathway:** GO: *miRNA-mediated gene silencing* (GO:0035195) / *ncRNA metabolic process* (GO:0034660).
* **Biological Rationale:** *MIR182* is a recognized oncogenic microRNA in multiple cancers (PMID: 22790015, PMID: 31908034) implicated in EMT, cell survival, and immune modulation. Non-coding RNAs act as competing endogenous RNAs (ceRNAs) or chromatin scaffolding complexes regulating tumor suppression and progression.
* **Evidence Strength & Limitations:** Literature support for *MIR182* in oncogenesis is strong. However, primary short-read RNA-seq datasets without specialized microRNA/small-RNA library preparation often exhibit poor quantification precision for small ncRNAs.

#### Program 5: Spliceosomal Pseudogene & Ribonucleoprotein (RNP) Machinery
* **Prognostic Association:** Risk-associated ($\text{HR} > 1$).
* **Major Supporting Genes:** *Y_RNA* ($\text{HR} = 5.1847055 \times 10^{21}$), *RNU6-1134P* ($\text{HR} = 2.0170925 \times 10^6$), *RNU4-72P* ($\text{HR} = 3.9239127 \times 10^{15}$), *RPL5P21* ($\text{HR} = 9381.9535$), *Metazoa_SRP* ($\text{HR} = 5.1847055 \times 10^{21}$).
* **Standardized Pathway:** Reactome: *Spliceosome* (R-HSA-72163) / GO: *Ribonucleoprotein complex* (GO:1990904).
* **Biological Rationale:** Y_RNAs and spliceosomal snRNA variants participate in DNA replication, RNA processing, and Ro60 RNP complex assembly (PMID: 32423154, PMID: 32944168). Overexpression of spliceosomal components reflects dysregulated RNA splicing and processing turnover in high-grade malignancies.
* **Evidence Strength & Limitations:** High representation in the input dataset (e.g., 168 rows for *Y_RNA*). High sequence similarity across snRNA pseudogenes creates substantial read-mapping ambiguities.

---

### 3. Key Genes and Interaction Modules

| Candidate Gene / Module | Input HR | Input Direction | Program Membership | Proposed Relationship Type | Biological & Network Context |
| :--- | :--- | :--- | :--- | :--- | :--- |
| **IRS4** | $5.1847055 \times 10^{21}$ | Risk | Program 3 (Metabolic Transport & Signaling) | **Regulatory Interaction** | Substrate binding to IGF1R/INSR drives downstream PI3K/AKT kinase activation. |
| **OTX2** | $5.1847055 \times 10^{21}$ | Risk | Program 1 (Transcriptional Reprogramming) | **Regulatory Interaction** | DNA-binding transcription factor regulating progenitor stemness networks. |
| **FOXR2** | $5.1847055 \times 10^{21}$ | Risk | Program 1 (Transcriptional Reprogramming) | **Direct Physical Interaction / Pathway Co-membership** | Forkhead factor interacting with histone acetyltransferase *KAT5* (STRING confidence = 0.911). |
| **SLC1A6** | $5.1847055 \times 10^{21}$ | Risk | Program 3 (Metabolic Transport & Signaling) | **Pathway Co-membership / Direct Physical Interaction** | Glutamate/aspartate symporter forming complexes with spectrin *SPTBN2* (STRING confidence = 0.950). |
| **MIR182** | $5.1847055 \times 10^{21}$ | Risk | Program 4 (Non-Coding RNA Networks) | **Regulatory Interaction** | Post-transcriptional target gene repression regulating EMT and inflammatory signaling (PMID: 31908034). |
| **FOXI1** | $6.6286512 \times 10^{13}$ | Risk | Program 1 (Transcriptional Reprogramming) | **Pathway Co-membership** | Forkhead family transcription factor involved in epithelial cell differentiation. |
| **CGB2** | $5.1847055 \times 10^{21}$ | Risk | Program 1 (Transcriptional Reprogramming) | **Pathway Co-membership** | Beta subunit of chorionic gonadotropin; oncofetal protein re-expressed in advanced solid tumors. |
| **CRH** | $1.5102345 \times 10^6$ | Risk | Program 2 (GPCR & Chemosensory Signaling) | **Regulatory Interaction** | Neuropeptide ligand binding CRHR1/CRHR2 to induce intracellular cAMP signaling. |
| **OR2M7 / OR5M10 / OR5T2 Cluster** | $5.1847055 \times 10^{21}$ | Risk | Program 2 (GPCR & Chemosensory Signaling) | **Pathway Co-membership / Putative Network Module** | Co-member olfactory receptors signaling via downstream G-proteins (*GNAL*, *GNB1*) and arrestins (*ARRB1*, *ARRB2*). |
| **CENPVL3** | $1.9287498 \times 10^{-22}$ | Protective | Program 4 / Chromatin Structural Module | **Indirect / Putative Relationship** | Pseudogene locus exhibiting protective survival association in dataset; functional target uncharacterized. |

*Note on interaction types:* Co-expression, pathway co-membership, or shared database annotations (e.g., STRING, Reactome) are distinguished from direct physical protein-protein interactions (such as *FOXR2*–*KAT5* or *SLC1A6*–*SPTBN2*).

---

### 4. Validation Priorities

```
+-----------------------------------------------------------------------------------+
|                            VALIDATION ROADMAP                                     |
+-----------------------------------------------------------------------------------+
  [Confounding Check]      -->  Filter out pseudogene/mapping artifacts & assess purity.
  [Mechanistic Hypothesis] -->  Validate IRS4-PI3K signaling & OTX2 transcriptional activation.
  [Biomarker]              -->  Target MIR182 / Y-RNA extracellular vesicles in independent cohorts.
  [Network Hypothesis]     -->  Assess ectopic OR2M7/OR5M10 GPCR signaling complexes.
  [Therapeutic Target]     -->  Evaluate SLC1A6 amino acid transport inhibition in vitro.
+-----------------------------------------------------------------------------------+
```

#### 1. Confounding & Technical Artifact Filtering (Confounding / Composition Check)
* **Priority Rationale:** Over 60% of the input features consist of non-coding pseudogenes (*S100A7P1*, *RPL5P21*, *HMGB3P27*), multi-copy snRNAs (*RNU6*, *RNU4*), and unmapped Ensembl IDs. The dataset exhibits mathematical saturation ($\text{HR} = 5.18 \times 10^{21}, P = 0$).
* **Input Dataset Signal:** Widespread extreme hazard ratios across pseudogenes and non-coding loci.
* **External Evidence:** High sequence homology between functional parent genes and pseudogenes frequently causes multi-mapping alignment artifacts in short-read RNA-seq.
* **Next Steps:** Re-align raw RNA-seq reads using unique-mapping parameters (e.g., STAR `--outFilterMultimapNmax 1`), perform tumor purity adjustment (ESTIMATE/ABSOLUTE algorithms), and re-fit penalized Cox models (Ridge/Lasso or Firth's correction).
* **Status:** **Exploratory hypothesis** (technical validation mandatory before biological extrapolation).

#### 2. Oncogenic Signaling via IRS4 Activation (Mechanistic Hypothesis)
* **Priority Rationale:** *IRS4* hyperactivates the PI3K/AKT pathway, driving cell survival and metabolic autonomy independent of upstream ligand stimulation.
* **Input Dataset Signal:** Highly elevated hazard ratio ($\text{HR} = 5.1847055 \times 10^{21}, P = 0, \text{FDR} = 0$).
* **External Evidence:** *IRS4* overexpression is documented in solid tumors as a driver of constitutive AKT phosphorylation and resistance to targeted therapies.
* **Next Steps:** Evaluate IRS4 protein expression by immunohistochemistry (IHC) in HCC tissue microarrays; perform siRNA/CRISPR knockdowns in HCC cell lines (e.g., HepG2, Huh7) to test AKT phosphorylation changes.
* **Status:** **Supported hypothesis**.

#### 3. Circulating MIR182 & Y_RNA Subtypes as Survival Biomarkers (Biomarker)
* **Priority Rationale:** Non-coding RNAs (*MIR182*, *Y_RNA*) are stable in extracellular vesicles and blood plasma, making them candidate non-invasive prognostic biomarkers (PMID: 32423154, PMID: 32944168).
* **Input Dataset Signal:** Strong risk associations in HCC OS analysis ($\text{HR} = 5.1847055 \times 10^{21}$).
* **External Evidence:** Independent literature establishes *MIR182* upregulation in aggressive carcinomas (PMID: 22790015) and plasma Y_RNA ratios in cell-type-specific stress responses.
* **Next Steps:** Quantify plasma EV-encapsulated *MIR182* and *Y_RNA* levels via RT-qPCR in an independent prospective cohort of HCC patients undergoing surgical resection; compute Kaplan-Meier OS curves.
* **Status:** **Supported hypothesis**.

#### 4. Ectopic Olfactory Receptor Signaling Network (Interaction / Network Hypothesis)
* **Priority Rationale:** Ectopic expression of *OR2M7*, *OR5M10*, and *OR5T2* suggests non-canonical GPCR signaling in HCC tissue.
* **Input Dataset Signal:** Co-occurrence of multiple olfactory receptor pseudogenes and functional genes as risk factors.
* **External Evidence:** STRING records link these receptors to G-protein subunits (*GNAL*, *GNB1*) and arrestins (*ARRB1*, *ARRB2*). Literature demonstrates ectopic ORs modulate intracellular $\text{Ca}^{2+}$ influx and cell motility.
* **Next Steps:** Co-immunoprecipitation and second-messenger ($\text{cAMP}/\text{Ca}^{2+}$) assays in primary HCC cell cultures exposed to OR ligand libraries.
* **Status:** **Exploratory hypothesis**.

#### 5. SLC1A6-Mediated Glutamate/Aspartate Uptake Inhibition (Therapeutic Target)
* **Priority Rationale:** High-affinity amino acid uptake via *SLC1A6* may support metabolic adaptation under tumor microenvironmental nutrient stress.
* **Input Dataset Signal:** Elevated risk hazard ratio ($\text{HR} = 5.1847055 \times 10^{21}$).
* **External Evidence:** QuickGO and Reactome annotate *SLC1A6* as a high-affinity L-aspartate/L-glutamate symporter. Cancer cells frequently depend on exogenous aspartate/glutamate for nucleotide synthesis and TCA cycle maintenance.
* **Next Steps:** Perform pharmacological inhibition or knockdown of *SLC1A6* in nutrient-deprived HCC cell cultures to evaluate metabolic vulnerability. *(Note: Target existence does not guarantee therapeutic efficacy).*
* **Status:** **Exploratory hypothesis**.

---

### 5. Evidence Grounding

The biological conclusions presented across programs, key genes, and priorities derive from distinct, explicit evidence categories:

1. **Direct Evidence from Input Dataset:**
   * Risk associations ($\text{HR} > 1$) for 97 genes including *CGB2*, *SLC1A6*, *IRS4*, *OTX2*, *FOXR2*, *MIR182*, *Y_RNA*, *CRH*, *FOXI1*.
   * Protective associations ($\text{HR} < 1$) for 3 genes (*CENPVL3*, *LOC105372753*, *RP11-506K19.2*).
   * *Limitation:* Effect sizes are mathematically saturated ($\text{HR} = 5.18 \times 10^{21}$ or $1.93 \times 10^{-22}$), representing unconstrained statistical estimates.
2. **Pathway & Ontology Evidence:**
   * Reactome pathways: *SLC-mediated transport of amino acids* (*SLC1A6*), *Generic Transcription Pathway* (*OTX2*, *FOXR2*, *FOXI1*).
   * GO Terms: *L-aspartate transmembrane transport* (GO:0070778), *miRNA-mediated gene silencing* (GO:0035195), *Detection of chemical stimulus in sensory perception* (GO:0007186).
3. **Protein Interaction & Regulatory Evidence:**
   * STRING interactions: *SLC1A6*–*SPTBN2* (confidence = 0.950), *FOXR2*–*KAT5* (confidence = 0.911), *OR2M7*/*OR5M10*/*OR5T2*–*ARRB1*/*ARRB2*/*GNAL*.
   * *Note:* Database records reflect prior functional assays or predictive modeling, not direct physical interactions calculated from this input file.
4. **Expression & Tissue-Specific Evidence:**
   * GTEx database indicates baseline *SLC1A6* and *OTX2* expression is restricted in healthy liver tissue, indicating tumor-specific reactivation or non-parenchymal cell expression.
5. **Published Literature Evidence:**
   * *MIR182* oncogenic roles in advanced carcinomas (PMID: 22790015, PMID: 31908034).
   * *Y_RNA* biomarker potential in circulating extracellular vesicles (PMID: 32423154, PMID: 32944168).
6. **Independent Statistical Validation:**
   * **Insufficient evidence:** No external cohort statistics were supplied in the input context; external statistical validation was not performed.

---

### 6. Limitations & Alternative Explanations

1. **Computational Model Failure & Mathematical Degeneracy:**
   * *Issue:* The occurrence of identical $\text{HR} = 5.1847055 \times 10^{21}$ across 69 genes and $\text{HR} = 1.9287498 \times 10^{-22}$ across protective genes indicates complete separation in unpenalized Cox regression models.
   * *Investigation:* Re-analyze survival data using penalized survival regression (L1/L2 Cox-net) or Firth's bias-reduced Cox regression to derive realistic hazard ratios and finite confidence intervals.
2. **Pseudogene Read-Mapping and Sequence Homology Artifacts:**
   * *Issue:* High representation of pseudogenes (*S100A7P1*, *RPL5P21*, *YWHAZP8*, *SNAI1P1*, *ALDH7A1P3*, *HMGB3P27*) and short non-coding RNAs (*RNU6*, *RNU4*, *RN7SK*) can result from cross-hybridization or misaligned reads belonging to highly expressed paralogous parent genes.
   * *Investigation:* Apply strict sequence alignment filters (e.g., masking pseudogene loci or enforcing zero-mismatch alignment) to determine whether pseudogene signals persist independently of parent gene expression.
3. **Tumor Purity & Tissue Cell-Composition Confounding:**
   * *Issue:* Bulk tumor transcriptomics averages signal across malignant hepatocytes, tumor-infiltrating lymphocytes, vascular endothelial cells, and hepatic stellate cells. Genes like *SLC1A6* or *CRH* may reflect infiltrating stromal or neural cell density rather than hepatocyte-intrinsic oncogenesis.
   * *Investigation:* Validate feature expression using single-cell RNA sequencing (scRNA-seq) or spatial transcriptomics of HCC tissues to resolve cell-type specific localization.
4. **Subgroup Overfitting & Unadjusted Clinical Covariates:**
   * *Issue:* Unadjusted Cox proportional hazards models fail to control for essential clinical confounders such as tumor stage (BCLC stage), viral etiology (HBV/HCV status), underlying cirrhosis (Child-Pugh score), or surgical resection margins.
   * *Investigation:* Perform multivariate Cox proportional hazards modeling incorporating age, sex, viral status, tumor stage, and treatment modality as co-variates.
5. **Association-versus-Causation Ambiguity:**
   * *Issue:* Statistical association with overall survival does not demonstrate functional driver status. Overexpressed genes may represent passive downstream passengers of genomic instability or stress responses.
   * *Investigation:* Conduct high-throughput CRISPR interference/activation (CRISPRi/a) screens in HCC cell lines to distinguish functional survival drivers from passive bystander transcripts.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=1, external claims checked=0, external mismatches=0, status=passed.

Answer model API: Google Gemini / gemini-3.6-flash

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 56/100 selected items (partially returned; some queries failed); cbioportal 57/100 selected items (records returned); chembl 5/100 selected items (partially returned; some queries failed); civic 1/100 selected items (records returned); clinicaltrials 5/100 selected items (records returned); clinvar 29/100 selected items (records returned); ensembl 19/100 selected items (partially returned; some queries failed); europepmc 305 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 78/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 14/100 selected items (records returned); humanbase 61/100 selected items (records returned); intact 10/100 selected items (partially returned; some queries failed); mygene 65/100 selected items (records returned); omnipath 6/100 selected items (records returned); opentargets 54/100 selected items (partially returned; some queries failed); pubmed 100 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 14/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 15/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 1/100 selected items (records returned); string 15/100 selected items (records returned); trrust 3/100 selected items (records returned)
